Aijun Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aijun Liao has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alexey V. Danilov
City of Hope National Medical Center
11 shared publications - Daniel Röth
Department of Immunology and Theranostics, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, California, United States of America
11 shared publications - Guido Marcucci
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA
11 shared publications - Jennifer R. Brown
Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
11 shared publications - Jianjun Chen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA
11 shared publications - Jingyi Jessica Li
Biostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
11 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Communications Biology
RNA-binding protein CIRBP mediates PKM2 intron retention to negatively regulate multiple myeloma progression and macrophage alternative activation
- 22 September 2026
- Published by Springer Nature in Communications Biology
Open AccessRNA-binding protein CIRBP mediates PKM2 intron retention to negatively regulate multiple myeloma progression and macrophage alternative activation
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- Open Access
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1529184
The role of complement in tumor immune tolerance and drug resistance: a double-edged sword
The domain of cancer treatment has persistently been confronted with significant challenges, including those associated with recurrence and drug resistance. The complement system, which serves as the foundation of the innate immune system, exhibits intricate and nuanced dual characteristics in the evolution of tumors. On the one hand, the complement system has the capacity to directly inhibit cancer cell proliferation via specific pathways, thereby exerting a beneficial anti-tumor effect. Conversely, the complement system can also facilitate the establishment of an immune escape barrier for cancer cells through non-complement-mediated mechanisms, thereby protecting them from eradication. Concurrently, the complement system can also be implicated in the emergence of drug resistance through a multitude of complex mechanisms, directly or indirectly reducing the efficacy of therapeutic interventions and facilitating the progression of cancer. This paper analyses the role of the complement system in tumors and reviews recent research advances in the mechanisms of tumor immune tolerance and drug resistance.
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1529184
Open AccessThe role of complement in tumor immune tolerance and drug resistance: a double-edged sword
The domain of cancer treatment has persistently been confronted with significant challenges, including those associated with recurrence and drug resistance. The complement system, which serves as the foundation of the innate immune system, exhibits intricate and nuanced dual characteristics in the evolution of tumors. On the one hand, the complement system has the capacity to directly inhibit cancer cell proliferation via specific pathways, thereby exerting a beneficial anti-tumor effect. Conversely, the complement system can also facilitate the establishment of an immune escape barrier for cancer cells through non-complement-mediated mechanisms, thereby protecting them from eradication. Concurrently, the complement system can also be implicated in the emergence of drug resistance through a multitude of complex mechanisms, directly or indirectly reducing the efficacy of therapeutic interventions and facilitating the progression of cancer. This paper analyses the role of the complement system in tumors and reviews recent research advances in the mechanisms of tumor immune tolerance and drug resistance.
- Top Cited PapersOpen Access
- 16 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of multiple myeloma, including estimates and 95% uncertainty intervals, were sourced from the 2021 Global Burden of Diseases Study. Furthermore, we explored the trends affecting the multiple myeloma burden from 1990 to 2021, breaking it down by demographic, age, and epidemiological factors. By 2021, the global incidence of multiple myeloma involved 148,754.63 reported cases, with confidence intervals ranging from 131,780.43 to 162,049.23. Worldwide, the number of mortality attributed to multiple myeloma reached 116,359.63, with the confidence interval lying between 103,078.62 and 128,470.57, and an age-standardized mortality rate of 1.37 per 100,000 individuals, the confidence interval for which was 1.22 to 1.52. There was a consistent increase in the incidence, prevalence, and disability-adjusted life years associated with multiple myeloma. Most of the disease burdens were seen in high income countries though its incidence is on the rise in low-income countries. Forecast for the years 2022–2050 showed the further increase in the incidence, prevalence, disability-adjusted life years, and age-standardized death rates of multiple myeloma.
- 16 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Top Cited PapersOpen AccessA systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of multiple myeloma, including estimates and 95% uncertainty intervals, were sourced from the 2021 Global Burden of Diseases Study. Furthermore, we explored the trends affecting the multiple myeloma burden from 1990 to 2021, breaking it down by demographic, age, and epidemiological factors. By 2021, the global incidence of multiple myeloma involved 148,754.63 reported cases, with confidence intervals ranging from 131,780.43 to 162,049.23. Worldwide, the number of mortality attributed to multiple myeloma reached 116,359.63, with the confidence interval lying between 103,078.62 and 128,470.57, and an age-standardized mortality rate of 1.37 per 100,000 individuals, the confidence interval for which was 1.22 to 1.52. There was a consistent increase in the incidence, prevalence, and disability-adjusted life years associated with multiple myeloma. Most of the disease burdens were seen in high income countries though its incidence is on the rise in low-income countries. Forecast for the years 2022–2050 showed the further increase in the incidence, prevalence, disability-adjusted life years, and age-standardized death rates of multiple myeloma.
- Open Access
- 2 November 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7, e44420
Patient Journey Toward a Diagnosis of Light Chain Amyloidosis in a National Sample: Cross-Sectional Web-Based Study
Background: Systemic light chain (AL) amyloidosis is a rare and multisystem disease associated with increased morbidity and a poor prognosis. Delayed diagnoses are common due to the heterogeneity of the symptoms. However, real-world insights from Chinese patients with AL amyloidosis have not been investigated. Objective: This study aimed to describe the journey to an AL amyloidosis diagnosis and to build an in-depth understanding of the diagnostic process from the perspective of both clinicians and patients to obtain a correct and timely diagnosis. Methods: Publicly available disease-related content from social media platforms between January 2008 and April 2021 was searched. After performing data collection steps with a machine model, a series of disease-related posts were extracted. Natural language processing was used to identify the relevance of variables, followed by further manual evaluation and analysis. Results: A total of 2204 valid posts related to AL amyloidosis were included in this study, of which 1968 were posted on haodf.com. Of these posts, 1284 were posted by men (median age 57, IQR 46-67 years); 1459 posts mentioned renal-related symptoms, followed by heart (n=833), liver (n=491), and stomach (n=368) symptoms. Furthermore, 1502 posts mentioned symptoms related to 2 or more organs. Symptoms for AL amyloidosis most frequently mentioned by suspected patients were nonspecific weakness (n=252), edema (n=196), hypertrophy (n=168), and swelling (n=140). Multiple physician visits were common, and nephrologists (n=265) and hematologists (n=214) were the most frequently visited specialists by suspected patients for initial consultation. Additionally, interhospital referrals were also commonly seen, centralizing in tertiary hospitals. Conclusions: Chinese patients with AL amyloidosis experienced referrals during their journey toward accurate diagnosis. Increasing awareness of the disease and early referral to a specialized center with expertise may reduce delayed diagnosis and improve patient management.
- 2 November 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7, e44420
Open AccessPatient Journey Toward a Diagnosis of Light Chain Amyloidosis in a National Sample: Cross-Sectional Web-Based Study
Background: Systemic light chain (AL) amyloidosis is a rare and multisystem disease associated with increased morbidity and a poor prognosis. Delayed diagnoses are common due to the heterogeneity of the symptoms. However, real-world insights from Chinese patients with AL amyloidosis have not been investigated. Objective: This study aimed to describe the journey to an AL amyloidosis diagnosis and to build an in-depth understanding of the diagnostic process from the perspective of both clinicians and patients to obtain a correct and timely diagnosis. Methods: Publicly available disease-related content from social media platforms between January 2008 and April 2021 was searched. After performing data collection steps with a machine model, a series of disease-related posts were extracted. Natural language processing was used to identify the relevance of variables, followed by further manual evaluation and analysis. Results: A total of 2204 valid posts related to AL amyloidosis were included in this study, of which 1968 were posted on haodf.com. Of these posts, 1284 were posted by men (median age 57, IQR 46-67 years); 1459 posts mentioned renal-related symptoms, followed by heart (n=833), liver (n=491), and stomach (n=368) symptoms. Furthermore, 1502 posts mentioned symptoms related to 2 or more organs. Symptoms for AL amyloidosis most frequently mentioned by suspected patients were nonspecific weakness (n=252), edema (n=196), hypertrophy (n=168), and swelling (n=140). Multiple physician visits were common, and nephrologists (n=265) and hematologists (n=214) were the most frequently visited specialists by suspected patients for initial consultation. Additionally, interhospital referrals were also commonly seen, centralizing in tertiary hospitals. Conclusions: Chinese patients with AL amyloidosis experienced referrals during their journey toward accurate diagnosis. Increasing awareness of the disease and early referral to a specialized center with expertise may reduce delayed diagnosis and improve patient management.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.